AllDocs -> cancers

P12.1.1 ROLE OF NOVEL THERAPIES TARGETING THE MYELOMA CELL AND ITS MICROENVIRONMENT Anderson KC Novel agents targeting MM cells in the BM, including Thalidomide (Thal) and ImmunomoduIatory Analogs Thal/IMiDs: induce G1 growth arrest/apoptosis of drug resistant MM cells via inhibiting NF-?B and activating caspase 8; inhibit adhesion of MM cells to BM stromal cells (SCs); inhibit bioactivity and/or secretion in MM cells and/or BMSCs of cytokines; inhibit angiogenesis; induce T cell and NK cell anti- MM immunity; and decrease human MM cell growth in a SCID mouse model. IMiD (Revamid) is more potent in preclinical studies and achieved stable disease or response in 79% patients in phase I study of relapsed refractory MM without somnolence, constipation, or neuropathy; it achieved responses, including CRs, in phase II trials. Phase III trial is comparing Dex/placebo versus Revimid/placebo in relapsed ...

1 RADIOLOGICAL MANAGEMENT OF SKELETAL METASTASES, MULTIPLE MYELOMA AND LYMPHOMA Maximilian F. Reiser, M.D. In malignant tumors distant metastases are of utmost importance for the choice among different treatment options. Depending upon the primary tumor, lung, liver and the skeletal system are frequent sites of distant metastases. The diagnosis of multiple myeloma is based on laboratory findings. For staging of this disease, plain radiograms of the skeletal system are obtained in order to assess skeletal involvement and fracture risk, especially of the spinal column. Lymphoma usually originate from the lymph nodes and staging is focussed on the visualization of the extent of lymph node involvement. In advanced stages of malignant lymphoma, the skeletal system may also be involved. Skeletal metastases, multiple myeloma and lymphoma are mainly distributed via the arterial circulation ...

CANCER Antineoplastics + stem cells in multiple myeloma 13 Busulfan : toxicity increased by concomitant metronidazole 20 Decitabine : fast-track designation in the US 22 Gefitinib approved in Australia 22 Gefitinib launched in the US 22 Human papillomavirus vaccines in ano-genital cancer 6 Metronidazole (concomitant) increases busulfan toxicity 20 ‘Metvix’ launched in the EU 22 Tariquidar in NSCLC: phase III trials discontinued 10 ASCO’s new conflict of interest policy 3 Cancer, treatment-related anaemia guidelines released 3 Cancer DM programme nets million dollar savings 5 US FDA approval endpoints for oncology drugs 4 CARDIO/VASCULAR Anticoagulants in cerebral sinus thrombosis 14 Cilostazol : beneficial effects in AV block 20 Epoprostenol improves Eisenmenger physiology 12 GP IIb/IIIa ...

MULTIPLE MYELOMA IN THE RAILROAD INDUSTRY __ R. Dean Hartley Hartley & O'Brien 827 Main Street Wheeling, West Virginia 26003 (304) 233-0777 Telephone (304) 233-0774 Telecopier HNOLAW@HGO.NET I. INTRODUCTION. The word " myeloma " means a tumor of the bone marrow. Most people develop many bone marrow tumors, hence the name "multiple myeloma ." Multiple myeloma is a neoplasm of mature and immature plasma cells. 1 These plasma cells characteristically cause destruction of bone, leading to such troublesome complications as bone pain, compression, fractures, hypercalcemia and renal damage. 2 Abnormal radiographs of the skeleton are found in 80 percent or more of patients at diagnosis. Multiple punched-out osteolytic lesions involving the red bone marrow are typical. 3 Complete remission is rare, and a possible cure has been reported ...

Multiple Myeloma Page 2 What is multiple myeloma ? Multiple myeloma is a type of cancer. Cancer occurs when cells in your body become abnormal and grow out of control. In multiple myeloma , it is the plasma cells that are effected. Plasma cells are a type of white blood cell found in your blood and bone marrow. Bone marrow is the spongy part inside bones and it is where your body makes the red blood cells, white blood cells and platelets found in your blood. Red blood cells carry oxygen to your muscles and tissues, white blood cells fight infection and platelets form a plug to stop bleeding. Plasma cells like the other white blood cells help your body fight infection. Plasma cells make antibodies or special proteins to fight certain bacteria or viruses. In multiple myeloma there are too many abnormal plasma cells ( myeloma cells). ...

Source: Finnish Medical Society Duodecim. Multiple myeloma (MM). Helsinki, Finland: Duodecim Medical Publications Ltd.; 2001 Dec 27. Multiple myeloma EBMG 27.12.2001 Contents Aim Pathology Epidemiology Aetiology Diagnosis Differential diagnostics Clinical picture Typical laboratory findings Basic examinations Additional investigations when MM is likely Complications Disease progression and prognosis Follow-up and treatment Bibliography Aim q Early diagnosis is important, especially in order to prevent irreversible kidney lesions. Pathology q MM is a clonal haematopoietic malignancy in which malignant plasma cells accumulate in the bone marrow and produce an immunoglobulin, usually monoclonal IgG or IgA (an M component). q Common complications ...

haematologica 2004; 89(2):February 2004 174 [haematologica] 2004;89:174-182 T HERESE S TANDAL H ENRIK H JORTH -H ANSEN T HOMAS R ASMUSSEN I NGER M ARIE S. D AHL S TIG L ENHOFF A NNE -T OVE B RENNE C ARINA S EIDEL V ADIM B AYKOV A NDERS W AAGE M AGNE B ØRSET A NDERS S UNDAN Ø YVIND H JERTNER Osteopontin is an adhesive factor for myeloma cells and is ...

U-266 Cell line U-266, human myeloma Transfection with Plasmid pEGFP-C1 (in bidistilled H 2 O) Electroporation buffer Eppendorf Hypoosmolar Electroporation Buffer (PH) Culture medium IMDM / 10 % FCS Cuvette Eppendorf, 2 mm gap width, 400 µl Temperature RT (20-25 °C) Reference Frau Pfeifer Universitätsklinikum Leipzig Molekulare Immunologie Johannisallee 30 D-04103 Leipzig Phone: +49 341 9725494 Fax: +49 341 9725489 1. Harvest the cells in the exponential growth phase and centrifuge them (for 5-10 minutes, 200 x g, at room temperature). 2. Resuspend the cells in IMDM / 0.5% FCS, determine the number of cells and centrifuge them (for 5-10 minutes, 200 x g, at room temperature). Remove supernatant. Note: The overall incubation time in the Eppendorf Electroporation Buffer must not exceed 30 minutes to guarantee a successful electroporation! ...

Multiple Myeloma Page 2 Multiple Myeloma is a B-cell malignancy characterized by accumulation of monclonal plasma cells. The multiple myeloma colon produces a monolonal Ig (M protein) of specific heavy and light chain subtype that can be identified on serum or urine protein electrophoresis Page 3 Diagnostic Criteria I I Multiple Multiple Myeloma Myeloma Major Criteria Major Criteria 1. 1. Plasmacytoma Plasmacytoma on tissue biopsy on tissue biopsy 2. Bone Marrow 2. Bone Marrow plasmacytosis plasmacytosis with more than 30% plasma cells. with more than 30% plasma cells. 3. Monoclonal globulin spike on serum electrophoresis exceeding 3. Monoclonal globulin spike on serum electrophoresis exceeding ...

023602113 œ case no. 5. Multiple Myeloma in a Dog Signalment: A 12-year, spayed female, 10 Kg, mixed breed dog. History: The dog presented with a 2-week history of weakness and inappetence. During the last 2 months, the dog had several episodes of sneezing and diarrhea, which resolved with an antibiotic treatment. The dog did not sneeze or had diarrhea during the last 3 weeks, and the owners did not notice any additional clinical signs. There were no previous medical problems. The dog was current on vaccinations. Physical examination: The dog was bright, alert, and responsive. The temperature was 40.5?c, the pulse was 128 beats/minute, and the respiratory rate was 35 breaths/minute. There was no evidence of nasal discharge, and the stools were firm on a rectal examination. The remainder of the physical examination was unremarkable. Case assessment: The ...

Leukemia, Lymphoma, and Myeloma Leukemia, lymphoma, and myeloma are cancers that originate in the bone marrow (in the case of leukemia and myeloma ) or in lymphatic tissues (in the case of lymphoma). Leukemia, lymphoma, and myeloma are considered to be related cancers because they involve the uncontrolled growth of cells with similar functions and origins. The diseases result from an acquired (not inherited) genetic injury to the DNA of a single cell, which becomes abnormal (malignant) and multiplies continuously. The accumulation of malignant cells interferes with the body's production of healthy blood cells and makes the body unable to protect itself against infections. Leukemia - Leukemia is a malignant disease (cancer) that originates in a cell in the marrow. Non-Hodgkin Lymphoma - Lymphoma is a general term for a group of cancers that originate in the lymphatic system. ...

Presenter ’ s Notes MULTIPLE MYELOMA MULTIPLE MYELOMA Page 2 Slide 2 This patient’s specific activities that will be reassessed are reading, working in the garden and enjoyment of family life. Slide 1 PS was diagnosed with multiple myeloma in August 1991. He was treated with melphelan/prednisone over 2 years PS was stable until June 1999, when haemoglobin started to decrease. He received 2 transfusions (2 units each) and commenced chemotherapy with idarubicin/prednisone in July 1999. Over the next 6 months, he gradually lost interest in activities of daily living. Page 3 Slide 3 PS required multiple transfusions during the first 6 months of the idarubicin/prednisone chemotherapy regimen. On many occasions, ...

MERIT ( MyEloma Renal Impairment Trial) A randomised controlled trial of adjunctive plasma exchange in patients with newly diagnosed multiple myeloma and acute renal failure (ISRCTN37161699) from the Renal Association and UK Myeloma Forum. Introduction MERIT is a new, multicentre, randomised controlled phase III trial, funded by the Leukaemia Research Fund and Cancer Research UK, and is included in the National Cancer Research Network Trials Portfolio. Primary question Does the addition of plasma exchange (PE) to chemotherapy increase the likelihood of renal recovery in patients with acute renal failure associated with newly diagnosed myeloma ? Primary endpoint - Proportion of patients alive and dialysis-independent at 100 days. Secondary aims - To determine whether addition of plasma exchange to chemotherapy affects overall survival - To ...

Highlighting the benefits of an early diagnosis The key message of this year’s Awareness Week is ‘Making Myeloma Manageable’ to highlight the benefits of an early diagnosis and a resulting benefit of an improved quality of life. We’re planning to target GPs throughout the UK and mail them an information pack outlining the main points to look out for when diagnosing patients. The campaign will be backed up by press awareness at both local and national level. Here’s how you can help Why not take the IMF (UK) ‘Making Myeloma Manageable’ information pack to all of your local family doctor practices? Ask them to put up a poster or distribute leaflets. We want to remind GPs of the early signs and symptoms of myeloma (back pain, fatigue and repeated infection) so they remember to carry out the necessary tests. Early diagnosis can help ensure that the impact of ...

Abstract. Cytogenetic investigation of multiple myeloma (MM) has been difficult by conventional methods and most of the data have been derived from western population where incidence of MM is much higher as compared to that of Asians. The current study represents the first report of chromo- somal aberrations of multiple myeloma in Chinese. We investigated 25 consecutive Chinese patients with MM for chromosomal aberrations at diagnosis using G-banding and multicolor spectral karyotyping (SKY). Of the 21 patients successfully analyzed by G-banding, 11 patients revealed cytogenetic abnormalities showing complex numerical and structural aberrations, which were further characterized with SKY. An abnormal karyotype significantly associated with blastic MM was observed. Consistent with the western literature, structural rearrangements involving chromosomes 1, 6, 8, 19, numerical abnormalities ...

Multiple Myeloma Statistical Tables and Highlights Multiple Myeloma - Number of Diagnosed Cancers and Average Annual Age-Adjusted Incidence Rates per 100,000 by Sex, Geographic Area, Race/Ethnicity, and Time Period, USA 1992-1996 and Colorado 1992-1996 and 1997 USA 1 1992-1996 Colorado 1992-1996 Colorado 1997 N Rate N Rate N Rate Male All Races 3292 5.5 434 5.5 103 6.1 White/Non-Hispanic 2592 5.1 356 5.2 85 5.8 White/Hispanic N/A N/A 47 6.9 9 5.8 Black 487 11.2 21 8.7 9 19.0 Female All Races 2954 3.7 339 3.3¢ 72 3.2 White/Non-Hispanic 2282 3.3 285 3.1 60 3.0 White/Hispanic N/A N/A 34 4.1 3 ...

N ORTHERN C ALIFORNIA C ANCER C ENTER , Cancer Incidence and Mortality in the Greater San Francisco Bay Area 131 Multiple Myeloma • Between 1988 and 2000, incidence rates of multiple myeloma stayed relatively constant (Table 1). • Rates were slightly higher in males than in females (Table 1). • Multiple myeloma was most common in blacks, for whom incidence rates were 2- to 3-times higher than rates for the other racial/ethnic groups (Table 1). • The occurrence of multiple myeloma was rare before age 40 and increased more rapidly with age in males than in females (Table 2). • Rates of multiple myeloma did not vary appreciably by county (Table 3). TABLE 1. Multiple Myeloma . Annual Case Counts, Age-Adjusted Incidence Rates ...

N ORTHERN C ALIFORNIA C ANCER C ENTER , Cancer Incidence and Mortality in the Greater San Francisco Bay Area 273 Multiple Myeloma TABLE 1. Multiple Myeloma . Annual Death Counts, Age-Adjusted Mortality Rates per 100,000 Population, a and 95% Confidence Intervals (CI), by Sex and Race/Ethnicity, 1988-2000, Greater San Francisco Bay Area b TOTAL MALES FEMALES Year Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI ALL RACES 1988-1993 c 1,125 3.8 3.6-4.1 564 4.6 4.3-5.1 561 3.3 3.0-3.6 1994 172 3.3 2.8-3.8 87 4.1 3.2-5.1 85 2.8 2.2-3.4 1995 202 3.8 ...

BAS 2/4/03 Multiple Myeloma Key Points: • Multiple Myeloma is a neoplastic proliferation of plasma cells • Clinical manifestations include bone pain, anemia, hypercalcemia, and renal insufficiency. • Diagnosis is a bone marrow biopsy with >10% plasma cells AND a plasma M-spike (>3g/dL) OR urine M-spike OR skeletal lytic lesions in the setting of typical clinical features. Definition • A neoplastic proliferation of a clone of plasma cells producing a monoclonal immunoglobulin Etiology • Unknown – exposure to radiation, benzene, herbicides, insecticides may play a role Epidemiology • Slightly more frequent in men than women; African Americans have 2X the rate as Caucasians • Median age at dx is 65; less than 3% are younger than 40 Clinical Manifestations • Bone pain is present in 2/3 at the time ...

Multiple Myeloma Page 2 NOTES Page 3 PATIENT INFORMATION BOOKLETS This booklet has been prepared by the Leukaemia F oundation to provide information and advice on the various types of leukaemias and associated blood diseases. Each booklet has been carefully written to answer most of the questions patients will have about the diagnosis and treatment of a particular disease. However, this does not mean that patients should assume the ideal treatment for them is described in these booklets. Treatment programs will be worked out in consultation with patients, taking into consideration the many special details that are relevant to an individual case. Clinical Haematologists associated with the Leukaemia F oundation are aware that the experience of undergoing treatment for cancer can be a difficult time, and that patients ...

Case Study of a Multiple Myeloma PS was diagnosed with multiple myeloma in August 1991. He was treated with melphela/prednisone over 2 years. PS was stable until June 1999, when haemoglobin started to decrease. He received 2 transfusions (2 units each) and commenced chemotherapy with idarubicin/prednisone in July 1999. Over the next 6 months, he gradually lost interest in daily living. The patient’s specific activities that will be reassessed are reading, working in the garden and enjoyment of family life. PS required multiple transfusions during the first six months of the idarubicin/prednisone regimen. On many occasions, 3 or 4 units were transfused. Haemoglobin remained low. In light of the patient’s multiple transfusions, an important aim of further treatment was to avoid the need for further blood transfusions and associated symptoms of anaemia 1 . The patient’s ...

myeloma Supportive Care in Myeloma T.J.LITTLEWOOD London June 2003 Complications of Myeloma Bone pain Anaemia Kidney damage Infection Supportive Care in Myeloma Key aspects Chemotherapy Prevention and treatment of complications Palliative care Emotional support Supportive care in Patients with Myeloma MM Aged 62 RAF officer Presented with back pain and fatigue Supportive care in Patients with Myeloma Investigations Anaemic Hb 9.3g/dl Myeloma protein level (IgG) 45g/l Urine protein (BJP) 1.5g/24h ...

Elaine Keane 1 The Role of IL-1 ß in Myeloma Cell Proliferation Elaine M. Keane IBS 522 Hypothesis Design and Scientific Writing April 20, 2000 Page 2 Elaine Keane 2 SPECIFIC AIMS: Multiple myeloma is a cancer of the plasma cells of the blood. In this cancer, a B cell divides uncontrollably and develops into an abnormal plasma cell, called a myeloma cell. Interleukin-1 ß (IL- 1 ß ) is a cytokine that has been shown to play an important role in the proliferation of cancerous plasma cells. IL-1 ß is not expressed by plasma cells from healthy individuals but is expressed by myeloma cells in virtually all patients with multiple myeloma . This differential expression of IL-1 ß suggests that IL-1 ß may be important in the pathogenesis ...

Mayo Clin Proc, January 2003, Vol 78 Editorial 15 of undetermined significance (MGUS) and recently pub- lished long-term follow-up of 1384 affected individuals, showing that 1% of persons with MGUS develop MM or a related disorder annually. 3 In the current report, 2 more than one third of the 1027 patients had a recognizable plasma cell proliferative disorder before the diagnosis of MM. Interestingly, survival did not differ in patients with or without preceding MGUS, was prolonged in patients with prior smoldering MM or plasmacytoma, and was shorter in patients with primary amyloidosis. Kyle et al 2 carefully review the presenting features to aid in our recognition and diagnosis of MM. Bone pain and fatigue related to anemia were common, whereas pares- thesias were uncommon; most patients had good perfor- mance status, perhaps ...

Mayo Clin Proc, January 2003, Vol 78 Newly Diagnosed Multiple Myeloma 21 Mayo Clin Proc . 2003;78:21-33 21 © 2003 Mayo Foundation for Medical Education and Research Original Article Review of 1027 Patients With Newly Diagnosed Multiple Myeloma R OBERT A. K YLE , MD; M ORIE A. G ERTZ , MD; T HOMAS E. W ITZIG , MD; J OHN A. L UST , MD, P H D; M ARTHA Q. L ACY , MD; A NGELA D ISPENZIERI , MD; R AFAEL F ONSECA , MD; S. V INCENT R AJKUMAR , MD; J ANICE R. O FFORD , BS; D IRK ...

Extracting causal knowledge from multiple myeloma gene expression data – Narayanan et al. 1 Extracting causal knowledge from multiple myeloma gene expression data Narayanan, A. * Tatineni. S. S. Bioinformatics Laboratory, School of Engineering & Computer Sciences, University of Exeter, Exeter, United Kingdom EX4 4QF Gamalielsson, J. Biocomputation Research Group, Department of Computer Science, University of Skövde, Box 408, 54128 Skövde, Sweden. _ ABSTRACT Motivation The aim is to apply artificial neural networks (ANNs) to myeloma gene expression data in order to extract causal rules that can be used for predicting myeloma . Current prediction and diagnostic methods for myeloma include detailed case histories, X-rays, MRI scans and biopsies. With increasing knowledge of gene regulatory networks (the way that genes switch each other on and off ...